期刊文献+

非透析慢性肾脏病患者心血管病危险因素的临床分析 被引量:1

原文传递
导出
摘要 目的:评估临床接受治疗的非透析的慢性肾脏病(CKD)患者心血管病(CVD)系列危险因素,为临床早期预防和治疗提供理论依据。方法:选择196例非透析CKD患者并根据肾小球滤过率(GRF)进行分期,同时选择30例健康人作为对照。根据身高、体重计算BMI,同时采血测定TC、TG、HDL-C、LDL-C、ALB、Hb、RBC、WBC、hs-CRP,留取24h尿液并测定尿总蛋白。结果:TC、TG及LDL-C水平在CKD1~2期呈上升趋势,自CKD3期开始下降。HDL-C从CKD1期开始呈现下降趋势,CKD4~5期HDL-C较对照组显著降低(P<0.05)。CKD各期WBC无显著变化,hs-CRP在CKD各期均呈逐渐升高趋势,CKD3期开始较对照组显著升高(P<0.01)。CKD各期ALB、Hb、RBC较对照组均显著降低(P<0.05)。CKD患者中24h尿蛋白较对照组均显著升高,其中CKD3期最高,显著高于CKD1~2期和CKD4~5期。结论:慢性非透析肾脏病住院患者多个心血管病危险因素均呈现高危变化,且随CKD分期而不同。因此,评估CKD患者CVD危险因素能为临床治疗决策提供依据。
出处 《临床血液学杂志(输血与检验)》 CAS 2012年第5期646-648,共3页 Journal of Clinical Hematology(Blood Transfusion & Laboratory Medicine)
  • 相关文献

参考文献10

  • 1WEINERD E. Public health consequences of chronic kidney disease[J]. Clin Pbarmacol Ther, 2009, 86 : 566 - 569.
  • 2Centers for disease control and prevention(CDC). Statespecific trends in chronic kidney failure, United States, 1990-2001[J]. MMWR Morb Mortal Wkly Rep, 2004, 53:918-920.
  • 3PETER A M, SUSAN S, KIRIT T, et al. Cardiovascular disease in chronic kidney disease: data from the kidney early evaluation program (KEEP)[J]. Curt Diab Rep, 2011,11:47-55.
  • 4DANIEl. E W, HOCINE T, MANISH G A, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all cause mortality: a pooled analysis of communitybased studies[J]. J Am Soc Nephrol, 2004,15:1307 - 1315.
  • 5杨晓,苏华.慢性肾脏病患者心血管疾病危险因素分析[J].医学新知,2011,21(3):168-171. 被引量:2
  • 6CHARLES R H, TERRY A J. Managing dyslipidemia in chronic kidney disease[J]. J Am Coil Cardiol, 2008,51 : 2375-2384.
  • 7SULIMAN M E, STENVINKEL P. Contribution of inflammation to vascular disease in chronic kidney disease patients[J]. Saudi J Kidney Dis Transpl, 2008,19 : 329 - 345.
  • 8FOUQUE D, APARICIO M. Eleven reasons to control the protein intake of patients with chronic kidney disease [J]. Nat Clin Pract Nephrol, 2007,3 : 383- 392.
  • 9高翔,梅长林.蛋白尿引起慢性肾脏病肾小管损伤的机制及治疗[J].中华肾脏病杂志,2008,24(3):210-213. 被引量:13
  • 10IRIE F,ISO H,SAIRENCHI T, et al. The relationships of proteinuria, serum creatinina, glomerular filtration rate with cardiovascular disease mortality in Japanese general population[J]. Kindey Int,2006,69 :1264- 1271.

二级参考文献67

  • 1侯凡凡,马志刚,梅长林,戎殳,黄颂敏,刘先蓉,袁伟杰,郭云珊,王莉,何强,王秀玲,桑晓红,栗霄立.中国五省市自治区慢性肾脏病患者心血管疾病的患病率调查[J].中华医学杂志,2005,85(7):458-463. 被引量:182
  • 2Buter H, Hemmelder MH, Navis G, et al. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant, 1998,13:1682-1685.
  • 3Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA, 2002,288:2421-2431.
  • 4Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med, 2002,347:1256-1261.
  • 5Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J Am Soc Nephrol, 2006, 17: 2974-2984.
  • 6Donadelli R, Abbate M, Zanchi C, et al. Protein traffic activates NF-kappaB gene signaling and promotes MCP-Idependent interstitial inflammation. Am J Kidney Dis, 2000, 36:1226-1241.
  • 7Wolf G, Ritz E, Combination therapy with ACE inhibitors and angiotensin Ⅱ receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int, 2005,67:799-812.
  • 8Del Vecehio L, Procaceio M, Vigano S, et al. Mechanisms of disease: the role of aldosterone in kidney damage and clinical benefits of its blockade. Nat Clin Pract Nephrol, 2007,3:42-49.
  • 9Douglas K, O'Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med, 2006, 145:117-124.
  • 10Attia DM, Verhagen AM, Stroes ES, et al. Vitamin E alleviates renal injury, but not hypertension, during chronic nitric oxide synthase inhibition in rats. J Am Sac Nephrol, 2001,12:2585-2593.

共引文献13

同被引文献3

引证文献1

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部